Supporting the

Neuroendocrine Cancer Community

Challenging Medical Certainty: The Key to Timely Neuroendocrine Tumour Diagnosis

Sep 18, 2023

‘… Part of the delay in diagnosing NETs is the overconfidence of the consulting doctor, who doesn’t doubt their own opinion that ‘there is nothing serious being missed’…. David Bartlett, GP.
Last week saw the 11th INCA Global NET Patient Advocate Summit take place in Bologna, Italy, bringing together representatives from each of the 33 member organisations of the International Neuroendocrine Cancer Alliance.
We were delighted that one of our Trustees, retired GP (and patient), David Bartlett, was invited to speak on the challenges faced by GPs in diagnosing a Neuroendocrine Tumour.
In his presentation, he said:
“We must make it possible to blend the understanding of the primary care physician (and the constraints with which they work under) and the NET patient. Only then will we move awareness and therefore diagnostic success, forward. If you can have the capacity to doubt your certainty, much more will be achieved.”
You can also listen to a Podcast David did for fellow GPs, with Manchester-based Primary Care Knowledge Boost on ‘An Approach to Rare Diseases in Primary Care’, where he explains further, the challenges which need to be overcome. Select here to listen.


The International Neuroendocrine Cancer Alliance (INCA) is the global voice in support of patients with Neuroendocrine Tumors (NETs) and genetic syndromes (GenNETs). INCA is an umbrella organisation representing 33 patient advocacy and research groups from around the world.
A key priority in INCA’s work is creating common platforms and working in collaboration with medical communities to fulfill the informational needs of patients, ensure access to the highest standards of care and facilitate patient involvement in research.